1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Genuv Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS) Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg) - Amyotrophic Lateral Sclerosis | Phase 1 / Phase 2 | Terminated | Genuv Inc. | 23 | 2020-04-02 | 2023-05-09 |
Amyotrophic Lateral Sclerosis (1)
Riluzole (1) · trametinib (1)
South Korea (1)
Byoung Joon Kim (1)